Keywords: Merck & Co, Alectos Thera, Alzheimer's, Licensing

Merck & Co snaps up Alectos Therapeutics’ Alzheimer’s compounds in deal worth $289 million

Article | 13 August 2010

Privately-held Canadian biopharmaceutical firm Alectos Therapeutics says it has entered into a research collaboration with US drug giant Merck & ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Alectos Therapeutics

Merck & Co

Go to company listing